MP02-12 TRENDS IN MIRABEGRON UTILIZATION IN THE UNITED STATES

Abstract

You have accessJournal of UrologyGeneral & Epidemiological Trends & Socioeconomics: Practice Patterns, Quality of Life and Shared Decision Making I (MP02)1 Apr 2020MP02-12 TRENDS IN MIRABEGRON UTILIZATION IN THE UNITED STATES Kevin Chua*, Hiren Patel, Alexandra Tabakin, Saikrishnaraya Doppalapudi, Charles Polotti, Elias Hyams, and Hari Tunuguntla Kevin Chua*Kevin Chua* More articles by this author , Hiren PatelHiren Patel More articles by this author , Alexandra TabakinAlexandra Tabakin More articles by this author , Saikrishnaraya DoppalapudiSaikrishnaraya Doppalapudi More articles by this author , Charles PolottiCharles Polotti More articles by this author , Elias HyamsElias Hyams More articles by this author , and Hari TunuguntlaHari Tunuguntla More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000000816.012AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Mirabegron was approved by the FDA in 2012 as the first beta-3 agonist to treat overactive bladder (OAB). This study aims to examine how prescribing patterns have changed since the approval of mirabegron. METHODS: The 2013-2017 Medicare Part D Public Use File was used to identify all prescribers of OAB medications including oxybutynin, tolterodine, trospium, darifenacin, solifenacin, fesoterodine, and mirabegron. The number of claims and total annual expenditure for each medication for all prescribers and urologists were analyzed from 2013-2017. RESULTS: In 2013, 124,702 prescribers (8,476 urologists and 116,226 non-urologists) made 6,312,157 OAB medication claims. By 2017, 131,474 prescribers (8,705 urologists and 122,769 non-urologists) made 6,956,005 OAB medication claims. From 2013 to 2017, the number of claims and proportion of OAB medication claims for mirabegron rose each year. In 2013, 140,401 claims were made for mirabegron which was 2.2% of OAB medication claims. In 2017, 1,617,439 claims were made for mirabegron which was 23.3% of OAB medication claims. Among all providers, from 2013 to 2017, oxybutynin was consistently the most commonly prescribed OAB medication comprising of 43% of all OAB medications in 2017. Among urologists, oxybutynin was the most commonly prescribed OAB medication from 2013-2015. However, in 2016, mirabegron became the most commonly prescribed OAB medication among urologists (31% of all claims). From 2013-2017 there has been a linear increase in the total annual expenditure on mirabegron among all providers and urologists. The total annual expenditure of mirabegron in 2017 by urologists was $298 million (45% of total annual expenditure by all providers for mirabegron). Additionally, among all providers and urologists, claims for solifenacin and darifenacin decreased each year. CONCLUSIONS: Mirabegron utilization and the total expenditure has steadily increased each year since it was approved in 2012, making it one of most prescribed OAB medications among urologists. Oxybutynin continues to be the most prescribed OAB medication when considering all physicians. Source of Funding: None © 2020 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 203Issue Supplement 4April 2020Page: e16-e16 Advertisement Copyright & Permissions© 2020 by American Urological Association Education and Research, Inc.MetricsAuthor Information Kevin Chua* More articles by this author Hiren Patel More articles by this author Alexandra Tabakin More articles by this author Saikrishnaraya Doppalapudi More articles by this author Charles Polotti More articles by this author Elias Hyams More articles by this author Hari Tunuguntla More articles by this author Expand All Advertisement PDF downloadLoading ...